Review article: Hepatitis C virus and calcineurin inhibition after renal transplantation

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 8, 2005, Pages 657-666

  Fabrizi, F ^a,b,d   Bromberg, J ^b   Elli, A ^a   Dixit, V ^c   Martin, P ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; AZATHIOPRINE; CALCINEURIN INHIBITOR; CONSENSUS INTERFERON; CORTICOSTEROID; CYCLOSPORIN A; CYCLOSPORIN A DERIVATIVE; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIM 811; OKT 3; PEGINTERFERON; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VALSPODAR; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG INHIBITION; DRUG MECHANISM; GRAFT INFECTION; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER CELL; LIVER DISEASE; LIVER FIBROSIS; LIVER GRAFT REJECTION; MICROEMULSION; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VIRUS REPLICATION;

CALCINEURIN; CYCLOSPORINE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; VIRUS REPLICATION;

EID: 26944452031     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02662.x     Document Type: Review

References (60)

1. Ponticelli C. Renal transplantation 2004: were do we stand today? Nephrol Dial Transplant 2004; 19: 2937-47.
2. Pereira BJG, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51: 981-99.
3. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002; 74: 427-37.
4. Vosnides GG. Nephrology Forum: hepatitis C in renal transplantation. Kidney Int 1997; 52: 843-61.
5. Bouthot BA, Murthy BVR, Schmid CH, Levey AS, Pereira BJG. Long-term follow-up of hepatitis C virus infection among organ transplant recipients. Transplantation 1997; 63: 849-53.
6. Stehman-Breen CO, Psaty BM, Emerson S, et al. Association of hepatitis C virus infection with mortality and graft survival in kidney-pancreas transplant recipients. Am J Kidney Dis 1997; 64: 281-6.
7. Legendre Ch, Garrigue V, Le Bihan C, et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65: 667-70.
8. Gentil MA, Rocha JL, Rodriguez-Algarra G, et al. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 1999; 14: 2455-60.
9. Lee WC, Shu KH, Cheng CH, Wu MJ, Chen CH, Lian JD. Long-term impact of hepatitis B, C virus infection on renal transplantation. Am J Nephrol 2001; 21: 300-6.
10. Breitenfeldt MK, Rasenack J, Berthold H, et al. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transplant 2002; 16: 130-6.
11. Forman JP, Tolkoff-Rubin N, Pascual M, Lin J. Hepatitis C, acute humoral rejection, and renal allograft survival. J Am Soc Nephrol 2004; 15: 3249-55.
12. Bruchfeld A, Wilczek H, Blinder CG. Hepatitis C infection, time in renal replacement therapy, and outcome after kidney transplantation. Transplantation 2004; 78: 745-50.
13. Morales JM, Dominguez-Gil B, Sanz-Guajardo D, Fernandez J, Escuin F. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant 2004; 18(Suppl. 3): S72-6.
14. Aroldi A, Lampertico P, Montagnino G, et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005; 79: 1132-6.
15. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Hepatitis C virus antibody and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5: 1452-61.
16. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Post-transplantation diabetes. A systematic review of the literature. Diabetes Care 2002; 25: 583-92.
17. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 2005 (in press).
18. Pollard S. Calcineurin inhibition and disease recurrence in the hepatitis C-virus positive liver transplant recipient. Liver Int 2004; 24: 402-6.
19. Vahlne A, Larsson PA, Horal P, et al. Inhibition of herpes simplex virus production in vitro by cyclosporin A. Arch Virol 1992; 122: 61-75.
20. Damaso CR, Keller SJ. Cyclosporin A inhibits vaccinia virus replication in vitro. Arch Virol 1994; 134: 303-19.
21. Luban J, Bossolt KL, Franke EK, Kaplana GV, Goff SP. Human immunodeficiency virus type 1 Gag protein binds to cyclophilin A and B. Cell 1993: 73: 1067-78.
22. Wainberg MA, Dascal A, Blain N, et al. The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type I. Blood 1988; 72: 1904-10.
23. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-3.
24. Watashi K, Hijakata M, Hosaka M, Yamaji M, Kunitada S. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282-8.
25. Matsuda A, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000; 47: 119-25.
26. Nakagawa M, Sakamoto N, Enomoto N, et al. Specific inhibition of hepatitis C virus replication by ciclosporin A. Biochem Biophys Res Commun 2004; 313: 42-7.
27. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984; 226: 544-7.
28. Hait WN, Harding MW, Handschumacher RE. Calmodulin. cyclophilin, and cyclosporin A. Science 1986; 233: 987-9.
29. Nilsson B, Anderson S. Proper and improper folding of proteins in the cellular environment. Ann Rev Microbiol 1991; 45: 607-35.
30. Paslaru L, Pinto M, Morange M. GRP 78 induction by cyclosporin A in human HeLa cells. FEBS Lett 1994; 350: 304-8.
31. Cotler SJ, Morrisey MJ, Wiley TE, Layden TJ, Jensen DM. A pilot study of the combination of cyclosporin A and Interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patients. J Clin Gastroenterol 2003; 36: 352-5.
32. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba A. Combined Interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003; 38: 567-72.
33. Kanamori H, Fukawa H, Maruta A, et al. Case-report: fulminant hepatitis C viral infection after allogeneic bone marrow transplantation. Am J Med Sci 1992; 303: 109-11.
34. Fan FS, Tzeng CH, Hsiao KI, Hu ST, Liu WT, Chen PM. Withdrawal of immunosuppressive therapy in allogeneic bone marrow transplantation reactivates chronic viral hepatitis C. Bone Marrow Transplant 1991; 8: 417-20.
35. Akiyama H, Yoshinaga H, Tanaka T, et al. Effects of cyclosporin A on hepatitis C virus infection in bone marrow transplant patients. Bone Marrow Transplant 1997; 20: 993-5.
36. Pariente EA, Goudeau A, Dubois F, et al. Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogeneic bone marrow transplantation. Dig Dis Sci 1988; 33: 1185-91.
37. Chen PM, Fan S, Liu CJ, et al. Changing of hepatitis B virus markers in patients with bone marrow transplantation. Transplantation 1990; 49: 708-13.
38. Feray C, Caccamo L, Alexander CJ, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis Group (EUROHEP). Gastroenterology 1999; 117: 619-25.
39. Berenguer M, Crippin J, Gish R, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38: 34-41.
40. Sheiner PA, Schwartz ME, Mor E, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30-34.
41. Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant 2001; 1: 197-203.
42. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-30.
43. Hunt J, Gordon FD, Lewis WD, et al. Histological recurrence and progression of hepatitis C after orthotopic liver transplantation - influence of immunosuppressive regimens. Liver Transplant 2001; 7: 1056-63.
44. Rosen HR, Shackleton CR, Hisa L, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92: 1453-7.
45. Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transplant 2004; 10: 1258-62.
46. o monitoring in de novo liver transplantation. Transplantation 2004; 77: 1632-8.
47. Zervos XA, Weppler D, Fragulidis GP, et al. Comparison of tacrolimus with neoral as primary immunosuppression in hepatitis C patients after liver transplantation. Transplant Proc 1998; 30: 1405-6.
48. Testa G, Crippin JS, Netto GJ, et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transplantation 2000; 6: 553-61.
49. Ben-Ari Z, Mor E, Bar-Nathan N, Shaharabani E, Shapira Z, Tur-Kaspa R. Comparison of tacrolimus with cyclosporin as primary immunosuppression in patients with hepatitis C virus infection after liver transplantation. Transplant Proc 2003; 35: 612-3.
50. Fisher RA, Stone JJ, Wolfe LG, et al. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation. Clin Transplant 2004; 18: 463-72.
51. Bahr MJ, Beckermann JGP, Rifai K, et al. Retrospective analysis of the impact of immunosuppression on the course of recurrent hepatitis C after liver transplantation. Transplant Proc 2005; 37: 1703-4.
52. Wiesner RH. A long-term comparison of tacrolimus (FK 506) versus cyclosporine in liver transplantation: a report of the United States FK 506 Study Group. Transplantation 1998; 66: 493-9.
53. Mueller AR, Platz KP, Willimski C, et al. Influence of immunosuppression on patient survival after liver transplantation for hepatitis C. Transplant Proc 2001; 33: 1347-9.
54. Duvoux C, Mennecier D, Pageaux G, Conti F, Roudot-Thoraval F, Dhumeaux D. Immunosuppression with tacrolimus and absence of anti-hypertensive therapy are associated with fibrosis progression after hepatitis C virus graft reinfection. Congr Int Soc Transplant 2002 (Abstract 2652).
55. Bucci JR, Matsumoto CS, Swanson SJ, et al. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol 2002; 13: 2974-82.
56. Morales JM, Campistol JM, Andres A, et al. Use of kidneys from anti-HCV positive donors. Transplant Proc 2001; 33: 1776-7.
57. Abbott KC, Bucci JR, Matsumoto CS, et al. Hepatitis C and renal transplantation in the era of modern immunosuppres sion. J Am Soc Nephrol 2003; 14: 2908-11.
58. Abbott KC, Lentine KL, Bucci JR, et al. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol 2004; 15: 3166-74.
59. Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Peters TG, Schnitzler MA. The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant 2004; 4: 2032-7.
60. Bloom RD, Sayer G, Fa K, Constantinescu S, Abt P, Reddy KR. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant 2005; 5: 139-44.